WuXi XDC and Boostimmune sign MoU for integrated services

Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform

Evonik and Heraeus cooperate to expand the range of services for highly potent API

Evonik specializes in mid- to large-scale, later clinical phase HPAPIs

Meissa Vaccines enters into CGMP manufacturing agreement for pediatric RSV vaccine candidate for Phase 2 clinical trials

Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials

Wacker Biotech partners with Caeregen Therapeutics on regenerative treatment for vision loss

As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands

Siegfried breaks ground on new R&D center for drug substances in Switzerland

The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth

Aurisco expands Oligonucleotide capacity

The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.

DualityBio collaborates with BioNTech to accelerate development of differentiated antibody-drug conjugate therapeutics

WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.

Bridgewest Group launches new sterile injectable CDMO NovaCina

Lonza and ABL Bio collaborate on development and manufacture of new bispecific antibody product

Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution

PCI Pharma plans Biologics assembly facility in the Midwest

New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies